JP2011520847A - 遅効型ｙ２及び／又はｙ４レセプターアゴニスト - Google Patents

遅効型ｙ２及び／又はｙ４レセプターアゴニスト Download PDF

Info

Publication number
JP2011520847A
JP2011520847A JP2011508945A JP2011508945A JP2011520847A JP 2011520847 A JP2011520847 A JP 2011520847A JP 2011508945 A JP2011508945 A JP 2011508945A JP 2011508945 A JP2011508945 A JP 2011508945A JP 2011520847 A JP2011520847 A JP 2011520847A
Authority
JP
Japan
Prior art keywords
ethoxy
xaa
seq
acetyl
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2011508945A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011520847A5 (enExample
Inventor
ソーレン オステルガール，
サンネ モラー クヌドセン，
ジェーン スペツラー，
ラスムス ヨルゲンセン，
ヤコブ コフォエド，
Original Assignee
ノボ・ノルデイスク・エー／エス
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノボ・ノルデイスク・エー／エス filed Critical ノボ・ノルデイスク・エー／エス
Publication of JP2011520847A publication Critical patent/JP2011520847A/ja
Publication of JP2011520847A5 publication Critical patent/JP2011520847A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2011508945A 2008-05-16 2009-05-18 遅効型ｙ２及び／又はｙ４レセプターアゴニスト Withdrawn JP2011520847A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP08156360 2008-05-16
EP08156360.3 2008-05-16
EP09154461 2009-03-05
EP09154461.9 2009-03-05
PCT/EP2009/055989 WO2009138511A1 (en) 2008-05-16 2009-05-18 Long-acting y2 and/or y4 receptor agonists

Publications (2)

Publication Number Publication Date
JP2011520847A true JP2011520847A (ja) 2011-07-21
JP2011520847A5 JP2011520847A5 (enExample) 2012-07-05

Family

ID=40934036

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011508945A Withdrawn JP2011520847A (ja) 2008-05-16 2009-05-18 遅効型ｙ２及び／又はｙ４レセプターアゴニスト

Country Status (12)

Country Link
US (1) US20110275559A1 (enExample)
EP (1) EP2279204A1 (enExample)
JP (1) JP2011520847A (enExample)
KR (1) KR20110017874A (enExample)
CN (1) CN102027007A (enExample)
AU (1) AU2009248041B2 (enExample)
BR (1) BRPI0912615A2 (enExample)
CA (1) CA2723855A1 (enExample)
IL (1) IL208836A0 (enExample)
MX (1) MX2010011845A (enExample)
RU (1) RU2504550C2 (enExample)
WO (1) WO2009138511A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022506070A (ja) * 2018-11-01 2022-01-17 イーライ リリー アンド カンパニー タンパク質チロシン－チロシン類縁体およびそれを使用する方法
JP2023522081A (ja) * 2020-04-17 2023-05-26 アイツーオー・セラピューティクス・インコーポレイテッド 長時間作用型ペプチドチロシンチロシン（ｐｙｙ）類似体及び使用方法

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2450374B9 (en) 2009-07-02 2016-11-23 Takeda Pharmaceutical Company Limited Peptide and use thereof
CN102573888A (zh) * 2009-09-18 2012-07-11 诺和诺德公司 长效y2 受体激动剂
EP2498800A1 (en) * 2009-11-13 2012-09-19 Novo Nordisk A/S Long-acting y2 receptor agonists
GB201001333D0 (en) * 2010-01-27 2010-03-17 Imp Innovations Ltd Novel compounds and their effects on feeding behaviour
WO2012006566A2 (en) 2010-07-09 2012-01-12 Amylin Pharmaceuticals, Inc. Microcrystalline y receptor agonists
MX377589B (es) 2010-12-16 2025-03-10 Novo Nordisk As Composiciones sólidas que comprenden agonista de glp-1 y sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico.
KR102072202B1 (ko) 2012-03-22 2020-01-31 노보 노르디스크 에이/에스 Ｇｌｐ-1 펩티드의 조성물 및 그것의 제조
RS58039B1 (sr) 2013-05-02 2019-02-28 Novo Nordisk As Oralno doziranje glp-1 jedinjenja
EP2842965A1 (en) 2013-09-03 2015-03-04 Gubra ApS Neuromedin U analogs comprising serum albumin binding amino acid residue
WO2015071355A1 (en) 2013-11-15 2015-05-21 Novo Nordisk A/S Selective pyy compounds and uses thereof
ES2732015T3 (es) * 2013-11-15 2019-11-20 Novo Nordisk As Compuestos de PYY selectivos y sus usos
WO2015073878A1 (en) * 2013-11-15 2015-05-21 Ur Diet, Llc Real-time satiety biofeedback
US10583172B2 (en) 2013-11-15 2020-03-10 Novo Nordisk A/S HPYY(1-36) having a beta-homoarginine substitution at position 35
US20240100450A9 (en) * 2014-01-17 2024-03-28 Repligen Corporation Sterilizing chromatography columns
EP3094391B1 (en) 2014-01-17 2024-11-20 Repligen Corporation Sterilizing chromatography columns
CN114805527A (zh) * 2014-05-21 2022-07-29 哈佛大学的校长及成员们 Ras抑制肽和其用途
MX392572B (es) * 2015-06-12 2025-03-24 Novo Nordisk As Compuestos del péptido yy (pyy) selectivos y sus usos.
AR114353A1 (es) 2018-02-02 2020-08-26 Novo Nordisk As Composiciones sólidas que comprenden un agonista del glp-1 y una sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico
GB201908426D0 (en) * 2019-06-12 2019-07-24 Imp College Innovations Ltd Appetite suppressing compounds
JP2024516395A (ja) 2021-04-27 2024-04-15 アードバーク・セラピューティクス・インコーポレイテッド 苦味受容体アゴニストおよび腸シグナル伝達化合物の組み合わせ

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007505840A (ja) * 2003-09-19 2007-03-15 ノボ　ノルディスク　アクティーゼルスカブ 新規ｇｌｐ−１誘導体
JP2007529463A (ja) * 2004-03-17 2007-10-25 ７ティーエム ファーマ エイ／エス 治療的介入のためのｙ４選択性レセプターアゴニスト
JP2007531711A (ja) * 2004-02-11 2007-11-08 アミリン・ファーマシューティカルズ，インコーポレイテッド 膵臓ポリペプチドファミリーモチーフおよびそのモチーフを含むポリペプチド
JP2008507477A (ja) * 2004-07-08 2008-03-13 ノボ　ノルディスク　アクティーゼルスカブ ポリペプチド延長タグ

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2123293A3 (en) * 2000-12-14 2010-09-08 Amylin Pharmaceuticals, Inc. Peptide YY and petide YY agonists for treatment of metabolic disorders
CN101222942A (zh) * 2005-07-18 2008-07-16 诺沃-诺迪斯克有限公司 用于治疗肥胖的肽

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007505840A (ja) * 2003-09-19 2007-03-15 ノボ　ノルディスク　アクティーゼルスカブ 新規ｇｌｐ−１誘導体
JP2007531711A (ja) * 2004-02-11 2007-11-08 アミリン・ファーマシューティカルズ，インコーポレイテッド 膵臓ポリペプチドファミリーモチーフおよびそのモチーフを含むポリペプチド
JP2007529463A (ja) * 2004-03-17 2007-10-25 ７ティーエム ファーマ エイ／エス 治療的介入のためのｙ４選択性レセプターアゴニスト
JP2008507477A (ja) * 2004-07-08 2008-03-13 ノボ　ノルディスク　アクティーゼルスカブ ポリペプチド延長タグ

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022506070A (ja) * 2018-11-01 2022-01-17 イーライ リリー アンド カンパニー タンパク質チロシン－チロシン類縁体およびそれを使用する方法
JP7280949B2 (ja) 2018-11-01 2023-05-24 イーライ リリー アンド カンパニー タンパク質チロシン－チロシン類縁体およびそれを使用する方法
JP2023082013A (ja) * 2018-11-01 2023-06-13 イーライ リリー アンド カンパニー タンパク質チロシン－チロシン類縁体およびそれを使用する方法
JP7851877B2 (ja) 2018-11-01 2026-04-27 イーライ リリー アンド カンパニー タンパク質チロシン－チロシン類縁体およびそれを使用する方法
JP2023522081A (ja) * 2020-04-17 2023-05-26 アイツーオー・セラピューティクス・インコーポレイテッド 長時間作用型ペプチドチロシンチロシン（ｐｙｙ）類似体及び使用方法

Also Published As

Publication number Publication date
RU2504550C2 (ru) 2014-01-20
EP2279204A1 (en) 2011-02-02
BRPI0912615A2 (pt) 2016-01-26
MX2010011845A (es) 2010-11-22
AU2009248041A1 (en) 2009-11-19
CA2723855A1 (en) 2009-11-19
KR20110017874A (ko) 2011-02-22
IL208836A0 (en) 2011-01-31
WO2009138511A1 (en) 2009-11-19
US20110275559A1 (en) 2011-11-10
AU2009248041B2 (en) 2013-10-03
CN102027007A (zh) 2011-04-20
RU2010149474A (ru) 2012-06-27

Similar Documents

Publication Publication Date Title
AU2009248041B2 (en) Long-acting Y2 and/or Y4 receptor agonists
JP4585037B2 (ja) アシル化ｇｌｐ−１化合物
ES2672770T3 (es) Derivados del péptido-1 similar al glucagón y su uso farmacéutico
JP5755398B2 (ja) 伸長されたｇｌｐ−１化合物
ES2532116T3 (es) Péptidos derivados con A-B-C-D y sus usos terapéuticos
AU2010203063B2 (en) Albumin-binding derivatives of therapeutic peptides
US9657079B2 (en) Truncated GLP-1 derivatives and their therapeutical use
JP6352806B2 (ja) 新規のグルカゴン類似体
AU2018338184B2 (en) Long-acting co-agonists of the glucagon and GLP-1 receptors
US20130040877A1 (en) Long-acting y2 receptor agonists
JP2013510829A (ja) 長時間作用型ｙ２受容体アゴニスト
TW201127397A (en) Growth hormones with prolonged in-vivo efficacy
KR20230022949A (ko) Glp1r 작용제 nmdar 길항제 접합체
BR112012029248B1 (pt) Análogo de glp-1 de fórmula i ou a sua composição, análogo de glp-1 de fórmula viii ou um sal farmaceuticamente aceitável ou a composição do mesmo, composição farmacêutica e uso de um composto
JP2008545644A (ja) 新規ポリ（エチレングリコール）誘導体とタンパク質へのそのカップリング方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120517

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120517

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140204

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140428

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140508

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140603

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140610

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140704

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20141008